Zydus Lifesciences Q4 Review – Excluding One-Offs, Earnings In Line With Estimates: Nirmal Bang

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Zydus Lifesciences Ltd.’s Q4 FY22 revenue and adjusted net profit (Rs 5,250 million) for inventory provisions were in-line with our estimates.

Zydus Lifesciences’ domestic branded portfolio growth is accelerating, growing by 13.8% YoY in Q4 FY22. This growth was led by market share gains in chronic segments like cardiovascular and anti-diabetes.

The biosimilar portfolio also grew faster than the rest of the domestic business.

The U.S. business declined in mid single digits on a QoQ and YoY basis due to heightened price erosion and supply chain challenges.

The consumer wellness business delivered on the back of a favorable seasonal quarter.

Click on the attachment to read the full report:


This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
honestcolumnist Governmental News Finance News

Source link

Back to top button